Hyperoxaluria - Pipeline Review, H1 2016

Date: May 25, 2016
Pages: 53
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H51156DF4BCEN
Leaflet:

Download PDF Leaflet

Hyperoxaluria - Pipeline Review, H1 2016

SUMMARY

Global Markets Direct’s, ‘Hyperoxaluria - Pipeline Review, H1 2016’, provides an overview of the Hyperoxaluria pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hyperoxaluria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperoxaluria and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Hyperoxaluria
  • The report reviews pipeline therapeutics for Hyperoxaluria by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hyperoxaluria therapeutics and enlists all their major and minor projects
  • The report assesses Hyperoxaluria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hyperoxaluria
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hyperoxaluria
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hyperoxaluria pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Hyperoxaluria Overview
Therapeutics Development
Pipeline Products for Hyperoxaluria - Overview
Hyperoxaluria - Therapeutics under Development by Companies
Hyperoxaluria - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Hyperoxaluria - Products under Development by Companies
Hyperoxaluria - Companies Involved in Therapeutics Development
Allena Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
OxThera AB
Hyperoxaluria - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALLN-177 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALLN-230 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALN-GO1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DB-027 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DCR-PH - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DCRPH-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxabact - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hyperoxaluria - Recent Pipeline Updates
Hyperoxaluria - Dormant Projects
Hyperoxaluria - Discontinued Products
Hyperoxaluria - Product Development Milestones
Featured News & Press Releases
May 13, 2016: Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1
May 05, 2016: FDA Grants Orphan Drug Designation to Allena’s Investigational Therapy for the Treatment of Pediatric Hyperoxaluria
Feb 10, 2016: Allena Pharmaceuticals Initiates Patient Treatment in Third Phase 2 Trial of ALLN-177 for Secondary Hyperoxaluria
Dec 21, 2015: Dicerna Begins Dosing in First Clinical Trial of Therapy for Primary Hyperoxaluria Type 1 in Healthy Volunteers
Nov 12, 2015: Allena Pharmaceuticals Announces Presentation of Successful Phase 2 Data from ALLN-177 Program at American Society of Nephrology Kidney Week
Nov 04, 2015: Allena Pharmaceuticals to Present Phase 2 Data on ALLN-177 Program at ASN Kidney Week 2015
Sep 02, 2015: Dicerna Pharmaceuticals Submits Investigational New Drug Application for DCR-PH1, an Investigational Therapy for Primary Hyperoxaluria Type 1 (PH1)
Aug 06, 2015: EMA Grants Orphan Drug Designation to DCR-PH1, Dicerna's Investigational Therapy for the Treatment of Primary Hyperoxaluria Type 1
Aug 04, 2015: Allena Pharmaceuticals Initiates Phase 2b Trial of ALLN-177 for Secondary Hyperoxaluria
Apr 23, 2015: FDA Grants Orphan Drug Designation for DCR-PH1, Dicerna's Investigational Therapy for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Hyperoxaluria, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Hyperoxaluria - Pipeline by Allena Pharmaceuticals, Inc., H1 2016
Hyperoxaluria - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016
Hyperoxaluria - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016
Hyperoxaluria - Pipeline by Digna Biotech, S.L., H1 2016
Hyperoxaluria - Pipeline by OxThera AB, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Hyperoxaluria Therapeutics - Recent Pipeline Updates, H1 2016
Hyperoxaluria - Dormant Projects, H1 2016
Hyperoxaluria - Discontinued Products, H1 2016

LIST OF FIGURES

Number of Products under Development for Hyperoxaluria, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

COMPANIES MENTIONED

Allena Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc.
Digna Biotech, S.L.
OxThera AB
Skip to top


Hyperoxaluria - Pipeline Review, H2 2016 US$ 2,000.00 Nov, 2016 · 44 pages
Hyperoxaluria - Pipeline Insights, 2016 US$ 1,000.00 Nov, 2016 · 60 pages
SIFI S.p.A - Product Pipeline Review - 2015 US$ 1,200.00 Apr, 2015 · 27 pages
Lipodystrophy - Pipeline Review, H1 2016 US$ 1,700.00 Mar, 2016 · 63 pages

Ask Your Question

Hyperoxaluria - Pipeline Review, H1 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: